Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors

[at noodls] – Granted Patents Provide Exclusivity for Potential Uses of Sapacitabine in Hematological Malignancies and Solid Tumors BERKELEY HEIGHTS, N.J., Feb. 12, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, … more

View todays social media effects on CYCCP

View the latest stocks trending across Twitter. Click to view dashboard

See who Cyclacel is hiring next, click here to view